Immunogenicity and Protective Efficacy of a Vero Cell Culture-Derived Whole-Virus H7N9 Vaccine in Mice and Guinea Pigs

• Walter Wodal,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Michael G. Schwendinger,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Helga Savidis-Dacho,

  Affiliation Pharmacology R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Brian A. Crowe,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Christine Hohenadl,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Richard Fritz,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Peter Brühl,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Daniel Portsmouth,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Anita Karner-Pichl,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Dalida Balta,

  Affiliation Process Development R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Leopold Grillberger,

  Affiliation Process Development R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• Otfried Kistner,

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• P. Noel Barrett ,

  * E-mail: noel_barrett@baxter.com

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯
• M. Keith Howard

  Affiliation Vaccine R&D, Baxter BioScience, Orth/Donau, Austria

  ⨯